Retinal Confusion: Rethinking the Central Mechanism in Myopia Management

For decades, the story of short-sightedness was told in the language of focus. The eye, we believed, grew too long because images landed behind the retina — hyperopic defocus — and lenses that pushed the focus forward could rein that growth back in. It is a tidy account, and it underpins most of the myopia-control lenses on the market today. But a growing body of evidence suggests the eye may not be listening to focus so much as to the quality and consistency of the contrast information reaching its photoreceptors — across both the macula and the periphery. A useful way to capture this is the idea of retinal confusion.

Defining retinal confusion

Retinal confusion is proposed here as an integrative term for a disturbance in the retina’s contrast-based growth signal: situations in which the retina receives spurious, excessive, or ambiguous contrast information that misleads the mechanism regulating eye growth. Crucially, it is not confined to central vision. It spans macular (central) function, where the cone mosaic encodes fine spatial detail, and peripheral function, which exerts a disproportionate influence over axial elongation. Framing the problem this way unifies genetics, environment, and optical treatment under a single question: is the retina receiving a clean growth signal, or a confused one?

Confusion at the macula: the genetic case

Some of the strongest evidence begins at the cone mosaic. Variations in the long- (L) and middle- (M) wavelength cone opsin genes — first mapped through Bornholm eye disease and later linked to common juvenile-onset myopia — reduce photopigment expression in a subset of cones. The result is a patchy mosaic with unequal sensitivity, which drives spurious activation of retinal contrast pathways even when no real image contrast is present. In effect, the central retina generates a confused, false-contrast signal. That the size of these genetic effects is among the largest reported for common myopia suggests this confusion sits close to the causal core of eye-growth control.

Confusion in the periphery

The periphery tells a complementary story. Experimental work shows that local changes in contrast produce regionally specific effects on eye growth, with peripheral retinal signals exerting a disproportionate influence on axial elongation and choroidal responses compared with the central retina. Reducing image contrast selectively in the peripheral field — for example through scattering lenses — thickens the peripheral choroid, an early marker of a growth-slowing response. The visual extent of an optical treatment zone across the peripheral retina also shapes how effectively growth is controlled. Retinal confusion, then, is as much about where contrast is disturbed as how much.

Why environment and genetics converge

The same lens explains long-standing epidemiology. Time spent outdoors — in visually complex but comparatively low-contrast natural scenes — is protective, whereas sustained near work and urban indoor settings are consistently linked to myopia. Analysis of the spatial-frequency content of everyday scenes shows that modern indoor and urban environments carry disproportionately high contrast energy in the mid spatial-frequency bands (around 3–4 cycles per degree) to which the retina’s growth-regulating circuitry is most sensitive. Whether the source is a genetic mosaic or a high-contrast screen, the outcome is the same: a confused retinal growth signal.

Why this may be the common pathway

Perhaps the most compelling argument is that even lenses designed around defocus may act by reducing retinal confusion. Optical characterisation shows that all lenslet architectures — DIMS, HALT, CARE — redistribute light in ways that also alter retinal image contrast, not only defocus. When lenses carrying opposite signs of peripheral defocus were tested head-to-head, both slowed axial growth equally — hard to reconcile with a purely sign-dependent focus mechanism, but consistent with a shared contrast-mediated signal. Contrast may be the common downstream pathway, with defocus geometry merely determining where across the retina the signal is cleaned up.

The clinical proof of concept

The most direct test is a lens that manages contrast and nothing else. Diffusion Optics Technology (DOT) spectacle lenses scatter light through thousands of non-refractive micro-diffusers, lowering retinal contrast without adding refractive power. Two randomised controlled trials — CYPRESS in North America and CATHAY in China — show these lenses slow axial elongation and refractive progression by roughly 50–75%, with benefit sustained over multiple years. The classic animal literature points the same way: severe form deprivation reliably induces myopia in primates, and high ambient lighting — which attenuates spurious contrast signalling — protects against it.

An honest caveat

The evidence is convergent but not yet closed. The exact retinal pathway by which contrast signals reach the sclera remains undefined, an alternative “noise-reduction” account of DOT lenses has been proposed, and whether disturbed contrast is truly the overarching mechanism or one cue among several has not been settled by studies directly linking retinal signalling to axial growth across designs. “Retinal confusion” is offered as a conceptual bridge, not a finished theory. But it captures something the focus-only account misses: that myopic eye growth may be driven by confused contrast information arising anywhere from the fovea to the far periphery — and that the goal of modern management is to give the retina a cleaner signal.

Research partnerships at the New Zealand Eye Research Centre

The New Zealand Eye Research Centre (NZERC) conducts and supports clinical research across myopia, keratoconus and dry eye disease. With clinician-led investigators, an established patient population and rigorous, protocol-driven data collection, NZERC is well positioned to serve as a New Zealand clinical trial site for both industry-sponsored and investigator-led studies.

Research organisations, device manufacturers and pharmaceutical sponsors seeking a capable and reliable trial site — whether in myopia control, keratoconus and corneal cross-linking, or ocular surface and dry eye disease — are invited to partner with NZERC on the design and delivery of high-quality clinical research.

For more information, or for the latest evidence on myopia management, keratoconus and dry eye disease, clinicians and practices are welcome to contact Rose Optometry for support and assistance with complex clinical cases.

References

• Neitz J, Neitz M. Diffusion optics technology (DOT): a myopia control spectacle lens based on contrast theory. Translational Vision Science & Technology. 2024;13(10):42.
• Neitz M, Wagner-Schuman M, Rowlan JS, Kuchenbecker JA, Neitz J. Insight from OPN1LW gene haplotypes into the cause and prevention of myopia. Genes. 2022;13(6):942.
• Neitz M, Neitz J. Intermixing the OPN1LW and OPN1MW genes disrupts the exonic splicing code causing an array of vision disorders. Genes. 2021;12(8):1180.
• Roth A, Breher K, Gisbert S, Arias A, Clement SP, Wahl S. Peripheral contrast reduction optically induced by scattering lenses thickens peripheral choroid. Translational Vision Science & Technology. 2024;13(10):32.
• Smith III EL. Optical treatment strategies to slow myopia progression: effects of the visual extent of the optical treatment zone. Experimental Eye Research. 2013;114:77-88.
• Flitcroft DI, Harb EN, Wildsoet CF. The spatial frequency content of urban and indoor environments as a potential risk factor for myopia development. Investigative Ophthalmology & Visual Science. 2020;61(11):42.
• Rose KA, Morgan IG, Ip J, et al. Outdoor activity reduces the prevalence of myopia in children. Ophthalmology. 2008;115(8):1279-85.
• Smith EL, Hung LF, Huang J. Protective effects of high ambient lighting on the development of form-deprivation myopia in rhesus monkeys. Investigative Ophthalmology & Visual Science. 2012;53(1):421-8.
• Laughton D, Hill JS, McParland M, et al. Control of myopia using diffusion optics spectacle lenses: 4-year results of a multicentre randomised controlled, efficacy and safety study (CYPRESS). BMJ Open Ophthalmology. 2024;9(1).
• Chen Z, Yang X, Liu L, et al. Randomized clinical trial of Diffusion Optics Technology spectacle lenses in a Chinese population (CATHAY): 12-month results. Ophthalmology Science. 2026:101150.
• Arias A, Ohlendorf A, Artal P, Wahl S. In-depth optical characterization of spectacle lenses for myopia progression management. Optica. 2023;10(5):594-603.
• Gawne TJ, Khanal S, Norton TT. An alternative mechanism for the anti-myopia effectiveness of diffusion optics technology (DOT) lenses. Translational Vision Science & Technology. 2025;14(1):15.